## Hazard assessment of aerosolized graphene-related nanomaterial in human epithelial lung tissue *in vitro*.

Barbara Drasler<sup>1</sup>, Melanie Kucki<sup>2</sup>, Alke Petri-Fink<sup>1</sup>, Barbara Rothen-Rutishauser<sup>1</sup>, Peter Wick<sup>2</sup>

## **Abstract**

Graphene-related materials (GRM) have promising properties for a wide range of new high-technology applications such as in electronics, photonics, and energy storage, resulting in mass production. However, concerns have been raised regarding their possible interaction with humans during the lifecycle, especially with the respiratory system, as being the primary route of exposure for airborne particles [1]. It has been shown that GRM can be respirable and thus can deposit beyond the ciliated airways following inhalation, resulting in pulmonary inflammation [2]. In the current study a 3D in vitro model of the human epithelial lung tissue barrier composed of epithelial cells, macrophages and dendritic cells [3] has been used for evaluating cell membrane permeability, (pro)inflammatory response (tumour necrosis factor alpha and interleukin-8 detection), as well as cell viability and oxidative stress induction after exposure to aerosolized GRM at different concentrations, corresponding to relevant GRM doses after inhalation exposure [4] (ranging from 0.2 to 1.5 µg/cm<sup>2</sup>). Material aerosolization was performed using the commercially available nebulizer VitroCell®Cloud system, coupled to the Quartz Crystal Microbalance for assessment of the aerosolized material deposition; the latter was additionally visualized using transmission electron microscopy (TEM, FEI Tecnai spirit) (Fig. 1). First results have shown that nebulization of graphene oxide (GO) resulted in a dose-dependent material deposition. None of the investigated parameters was elevated for all the concentrations tested. Further investigations are ongoing to assess effects after a prolonged exposure to GO and different types of GRM such as graphene nanoplatelets, which are forecast to represent a majority of the market value of the graphene market in the year 2026 [5].

## References

- [1] Oberdorster G, Stone V, Donaldson K, Nanotoxicology, 1 (2007) 2-25.
- [2] Schinwald A, Murphy FA, Jones A, Macnee W, Donaldson K, Acs Nano 6 (2012) 736-746.
- [3] Rothen-Rutishauser BM, Kiama SG, Gehr P, Am J Resp Cell Mol 32 (2005) 281-289.
- [4] Su WC, Journal of Occupational and Environmental Hygiene 13 (2016) 48-59.
- [5] Ghaffarzadeh K. Report: Graphene, 2D Materials and Carbon Nanotubes: Markets, Technologies and Opportunities 2016-2026. Published by: IDTechEx, March, 2016. (http://www.idtechex.com/research/reports/graphene-2d-materials-and-carbon-nanotubesmarkets-technologies-and-opportunities-2016-2026-000465.asp)

## **Figures**




Fig. 1: Transmission electron micrograph of aerosolized (nebulized) graphene oxide.

<sup>&</sup>lt;sup>1</sup> BioNanomatrials group, Adolphe Merkle Institute, University of Fribourg, Chemin des Verdiers 4, 1700 Fribourg, Switzerland

<sup>&</sup>lt;sup>2</sup> Laboratory for Particles-Biology Interactions, Empa - Swiss Federal Laboratories for Materials Science and Technology, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland barbara.drasler@unifr.ch